Daily Newsletter

14 September 2023

Daily Newsletter

14 September 2023

Two FDA wins for Annalise.ai’s hydrocephalus triage tool

The FDA has granted 510(k) clearance and breakthrough device designation to the company’s obstructive hydrocephalus CT scan software.

Robert Barrie September 14 2023

Annalise.ai’s portfolio of artificial intelligence (AI)-powered triage software has expanded, after the US Food and Drug Administration (FDA) cleared the company’s obstructive hydrocephalus radiological software.

The 510(k) clearance, which is for the triage and notification of the brain condition on non-contrast brain CT scans, means radiology professionals can now have assistance from the software in prioritising patients suspected with obstructive hydrocephalus.

The tool uses algorithms to assist clinicians in identifying suspected critical findings on non-contrast head CT studies and help optimise radiology workflow. 

Obstructive hydrocephalus occurs when there is an accumulation of cerebrospinal fluid along the passages between brain ventricles.  It is a potentially life-threatening condition.

The FDA, seeing the necessity for accurate and quick triaging tools for the condition, also granted the software breakthrough device designation. Annalise.ai said this is the first radiology triage device to receive this accolade.

The recent clearance brings the Delaware, US-based company’s total FDA-cleared CT scan algorithms to five. The algorithms reside on its Enterprise CTB platform, which the company states can detect up to 130 radiological findings.

Annalise.ai also has five FDA-cleared tools for chest X-rays, meaning the company possesses 10 FDA clearances in total.

AI use in medical imaging is transforming clinical workflows by significantly increasing the throughput of image processing and assisting clinicians in identifying areas of interest – leading to quicker patient prioritisation.

According to a report by GlobalData, global revenue for AI platforms across healthcare will reach $4.3bn by 2024. The CAGR between 2019 and 2024 will be 24.6% and 20.6% in healthcare and medical devices respectively.

Dr Rick Abramson, chief medical officer at Annalise.ai, added: “Our advanced algorithms support radiologists by facilitating prioritization of non-contrast head CT studies with suspected critical findings, thereby optimizing radiology workflow. With its set of clearances, Annalise.ai promotes faster report turnaround times by identifying and elevating critical cases for immediate attention.”

Generative AI set to transform the medical devices industry

Generative AI can improve personalized healthcare by collecting data from patients via wearable devices, which can provide continuous, real-time data that can complement traditional data sources such as imaging, patient records, and more. It can also enhance existing imaging techniques by generating high-quality images of organs using data from low-resolution images (such as ultrasounds). However, the collection and use of patient healthcare data through AI medical products could conflict with regulations around the globe.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close